Hutan Ashrafian is chief scientific officer of Flagship Pioneering’s Preemptive Health &amp; Medicine Initiative and is chief medical officer at Apriori Bio. He is a senior clinician-scientist and surgeon with extensive experience developing novel biomedical and technological methods to address a wide range of healthcare issues. He has worked with Google to co-develop an AI algorithm to determine cancer from breast screens and has led STARD-AI and spearheaded NICE’s AI HTA standards. He is co-editor-in-chief of Springer Nature’s comprehensive reference text of AI in Medicine.Hutan has held multiple scientific and clinical positions including: chief scientific adviser at the Institute of Global Health Innovation and chief medical officer at Oxford Medical Products Ltd. His wide-ranging work has been published in over 500 peer-reviewed publications in a variety of leading journals including Nature, The Lancet and The New England Journal of Medicine.Hutan earned his degree in medicine at University College London where he also received an honors degree in immunology and cell pathology. He holds a PhD in computational physiology and metabolic surgery from Imperial College London and a health economics-focused MBA with distinction from Warwick Business School.

large_Hutan Ashrafian-New.jpg

Hutan Ashrafian, MD, PhD, MRCS, MBA

CMO, Apriori Bio

Chief Scientific Officer, Preemptive Health & Medicine Initiative, Flagship Pioneering